(¿Â¶óÀÎ) Á¦46Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦6Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 : 2020-11-12±³À°ÀÏÀÚ : 2020-11-12
±³À°Àå¼Ò : ¿Â¶óÀÎ ¿¬¼ö±³À°(½Ç½Ã°£ È»ó °ÀÇ)
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) Á¦46Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦6Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 ÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486
À̸ÞÀÏ :
cancer4@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ,
Âü¼®¿¹»óÀοø : 900¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 13 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í 1.ȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 5¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 2¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 5¸¸¿ø 2. ºñȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 7¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 3¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 7¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 09:40~10:20 Viral and cellular immunotherapeutics for cancer: From research to clinical care Yuman Fong(City of Hope Medical Center)
±³À°½Ã°£ 11¿ù 12ÀÏ Room B 15:20~15:50 Is sphincter preservation the best way for rectal cancer? °¼º¹ü(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11¿ù 12ÀÏ Room B 15:50~16:20 Microsurgical treatment of lymphedema: Upper extremity and lower extremity ±èÁÖÇü(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 11¿ù 12ÀÏ Room B 16:20~16:50 Function preserving surgery for gastric cancer ¾ÈÁö¿µ(¼º±Õ°üÀÇ´ë)
Åä·Ð 11¿ù 12ÀÏ Room B 16:50~17:00 Q&A Discussion ()
±³À°½Ã°£ 11¿ù 12ÀÏ Room B 13:30~13:55 Frontiers in theranostics ¹Ú¿µÁÖ(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 11¿ù 12ÀÏ Room B 13:55~14:20 Spectroscopic tissue scanner for diagnosis of gastric cancer À±È«¸¸(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 11¿ù 12ÀÏ Room B 14:20~14:45 Integrative multi-omics analysis reveals consensus molecular subtypes reflecting distinct clinical phenotypes of hepatocellular carcinoma À̼ºÈ¯(Â÷ÀÇ´ë)
±³À°½Ã°£ 11¿ù 12ÀÏ Room B 14:45~15:10 Impact of wound healing on ovarian cancer progression and sensitivity to platinum based agent ÀÌÀ¯¿µ(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 10:30~10:55 NTRK fusion-positive cancers and TRK inhibitor therapy David S. Hong(MD Anderson Cancer Center)
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 10:55~11:20 Exploring the best treatment options for BRAF-mutant Hussein A. Tawbi(MD Anderson Cancer Center)
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 11:20~11:45 Analysis of TMB and MSI Status and their treatment outcomes ÇѼ¼¿ø(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 11:45~12:10 DNA damage pathways for cancer treatment ¹Ú¿¬Èñ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11¿ù 12ÀÏ Room B 10:30~10:55 Oncogenic IRS4 activation in thymic epithelial tumors ÁÖ¿µ¼®(KAIST)
±³À°½Ã°£ 11¿ù 12ÀÏ Room B 10:55~11:20 Cross-species oncogenic signatures of breast cancer in canine mammary tumors ±è»ó¿ì(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11¿ù 12ÀÏ Room B 11:20~11:45 Recent update of breast cancer genomics ÇÑ¿ø½Ä(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11¿ù 12ÀÏ Room B 11:45~12:10 Systems biology approach to overcome the therapeutic resistance to multikinase inhibitor ¿øÀç°æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 13:30~13:55 History and current status of AYA oncology ÇÑÁ¤¿ì(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 13:55~14:20 Sarcomas in AYA ÀÌÁؾÆ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 14:20~14:45 Fertility preservation in female AYA with cancers ÀÌÁ¤·Ä(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 14:45~15:10 Survivorship of AYA with cancers Á¶ÁÖÈñ(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 15:20~15:45 The power of ONE: Immunology in the age of single cell genomics Ido Amit(Weizmann Institute of Science)
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 15:45~16:10 Utilizing machine intelligence for neoantigen identification ÃÖÁ¤±Õ(KAIST)
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 16:10~16:35 Machine learning-based immunogenomic analysis of TIME to predict immune directed therapy response in GC Á¤ÀçÈ£(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 16:35~17:00 Significance of tumor-specific and non-specific T cells in cancer immunotherapy ½ÅÀÇö(KAIST)
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 08:30~09:30 Outstanding Abstract Session ¹ÌÁ¤()
±³À°½Ã°£ 11¿ù 12ÀÏ Room B 08:30~09:30 Satellite Symposium ¹ÌÁ¤()
±³À°½Ã°£ 11¿ù 12ÀÏ Room A 12:40~13:20 More TOMORROWs: Pembrolizumab will double the hope for mNSCLC patients in the 1st line ±èÇý·Ã(¿¬¼¼ÀÇ´ë)